Is Incyte Corporation (INCY) a Buy, Sell, or Hold?
Incyte Corporation
NASDAQ:INCY
$115.09 USD
$0.21 (0.18%)
- Volume
- 1.51M
- Average Volume
- 1.73M
- Market Capitalization
- $22.99B
- P/E Ratio
- 15.77
- Dividend Yield
- 0.00%
- Price Target
- $108.50
- Year High
- $118.97
- Year Low
- $67.17
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.68
| Source | Headline |
|---|---|
|
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarciba gurufocus.com - 2026-07-13 04:00:00 |
|
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types. businesswire.com - 2026-07-13 04:00:00 |
|
2 Fast-Growing Pharmaceutical Stocks to Buy Now
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings. fool.com - 2026-07-08 20:05:00 |
|
Incyte to Report Second Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13759. businesswire.com - 2026-07-08 08:00:00 |
|
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio. businesswire.com - 2026-07-06 08:39:00 |
|
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion
Three outlier inflow signals push biopharmaceutical firm Incyte Corporation (INCY) up 71% in a year. fxempire.com - 2026-07-03 11:58:35 |
|
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment. zacks.com - 2026-06-29 14:41:13 |
|
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 2026-06-29 10:55:55 |
|
Incyte: New Catalysts Support Another Leg Higher
Incyte Corporation remains a strong long pick, with a maintained 'Buy' rating and a 40% upside to a $159.5/share price target. Recent catalysts include a positive CHMP opinion for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding INCY's product portfolio and reducing Jakafi concentration risk. Q1 2026 results showed robust diversification: revenues up 21% YoY, adjusted EPS up 56% YoY, and ex-Jakafi sales up 63% YoY. seekingalpha.com - 2026-06-29 08:35:54 |
|
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi gurufocus.com - 2026-06-26 08:00:00 |
|
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis. businesswire.com - 2026-06-26 07:30:00 |
|
Here Are Monday's Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, SpaceX, and More
Futures are trading mixed as we prepare to finish the last full week of the second quarter. 247wallst.com - 2026-06-22 08:02:21 |
|
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2026-06-19 10:51:07 |
|
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for Adults with Relapsed or Refractory DLBCL. businesswire.com - 2026-06-19 02:00:00 |
|
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date. zacks.com - 2026-06-17 07:51:07 |
|
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date. zacks.com - 2026-06-16 04:56:04 |
|
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date. zacks.com - 2026-06-15 11:45:34 |
|
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilur gurufocus.com - 2026-06-14 17:00:00 |
|
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP. businesswire.com - 2026-06-14 16:35:00 |
|
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essenti
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in- gurufocus.com - 2026-06-13 12:00:00 |
|
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET. businesswire.com - 2026-06-13 11:15:00 |
|
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min gurufocus.com - 2026-06-13 06:00:00 |
|
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--Results from Incyte's frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination at the 2026 EHA Plenary Showed Prolonged Progression Free Survival. businesswire.com - 2026-06-13 06:00:00 |
|
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings
Biotech stock Incyte is working its way up toward a pivot at 112.29, extending a two-day winning streak. investors.com - 2026-06-11 13:48:06 |
|
Here's Why Incyte (INCY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2026-06-11 10:40:34 |
|
Incyte: I Am Moving From Hold To Buy
Incyte is upgraded to Buy as pipeline progress and improved EPS estimates offset Jakafi concentration risk. frontMIND Phase 3 data for Monjuvi in first-line DLBCL is promising, supporting potential market share gains despite emerging competition. INCY acquired Vega Therapeutics, adding VGA039 to its hematology portfolio. seekingalpha.com - 2026-06-10 01:01:14 |
|
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
Incyte will acquire Vega Therapeutics for up to $2B, adding late-stage VWD candidate VGA039 and expanding its hematology growth prospects. zacks.com - 2026-06-09 16:31:16 |
|
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential
Incyte Corporation (NASDAQ:INCY) said Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal valued at $1.25 billion upfront. benzinga.com - 2026-06-09 14:08:29 |
|
Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript seekingalpha.com - 2026-06-09 11:42:09 |
|
Incyte Corporation (INCY) M&A Call Transcript
Incyte Corporation (INCY) M&A Call Transcript seekingalpha.com - 2026-06-08 10:58:33 |
|
Here's Why Incyte (INCY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2026-06-08 10:45:36 |
|
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Incyte (Nasdaq:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeut gurufocus.com - 2026-06-08 08:00:00 |
|
Incyte to Buy Vega Therapeutics For Up to $2 Billion
Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company's hematology portfolio into bleeding disorders. wsj.com - 2026-06-08 07:34:00 |
|
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary
Incyte said on Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its pipeline for blood disorder therapies. reuters.com - 2026-06-08 07:07:54 |
|
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders. businesswire.com - 2026-06-08 07:00:00 |
|
Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports
US biotech Incyte Pharma is nearing a deal for up to $2 billion to buy blood disorder drug developer Star Therapeutics, the Financial Times reported on Sunday, citing people familiar with the matter. reuters.com - 2026-06-07 06:11:12 |
|
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgiser gurufocus.com - 2026-06-04 09:00:00 |
|
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for ENDO 2026. businesswire.com - 2026-06-04 08:05:00 |
|
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min gurufocus.com - 2026-05-30 09:00:00 |
|
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or death by 25% compared to the standard alone, but with a higher rate of study dropouts due to side effects. reuters.com - 2026-05-30 08:02:07 |
|
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's frontMIND trial found Tafasitamab (Monjuvi/Minjuvi) combo significantly prolongs progression-free survival in high-risk DLBCL patients. businesswire.com - 2026-05-30 08:00:00 |
|
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? zacks.com - 2026-05-28 12:31:17 |
|
Here's Why Incyte (INCY) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 2026-05-26 10:51:15 |
|
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. E gurufocus.com - 2026-05-26 09:00:00 |
|
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out
Incyte NASDAQ: INCY Chief Medical Officer Steven Stein outlined the company's development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989, during a company news event. marketbeat.com - 2026-05-25 12:02:59 |
|
Here's Why Incyte (INCY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 2026-05-22 10:41:14 |
|
Why Incyte (INCY) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2026-05-21 10:46:11 |
|
Inside Incyte's $120 Million AI For Drug Development Deal
In this week's edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure's $7 billion valuation, and more. To get it in your inbox, subscribe here. forbes.com - 2026-05-20 12:10:19 |
|
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
[url="]Incyte[/url] (Nasdaq:INCY) and [url="]Genesis Molecular AI[/url] today announced a significant expansion of their strategic collaboration building and d gurufocus.com - 2026-05-20 09:00:00 |
|
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
WILMINGTON, Del. & SAN MATEO, Calif.--(BUSINESS WIRE)--Incyte and Genesis expand molecular AI collaboration to accelerate drug discovery. businesswire.com - 2026-05-20 08:00:00 |
